YUNG ZIP CHEMICAL IND. CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.15 TWD | 0.00% |
|
+1.36% | -6.42% |
| Sales 2022 | 567M 17.53M 1.46B | Sales 2023 | 559M 17.28M 1.44B | Capitalization | 1.68B 51.98M 4.34B |
|---|---|---|---|---|---|
| Net income 2022 | 70M 2.16M 181M | Net income 2023 | 62M 1.92M 160M | EV / Sales 2022 | 2.82 x |
| Net Debt 2022 | 70.11M 2.17M 181M | Net Debt 2023 | 28.18M 871K 72.74M | EV / Sales 2023 | 3.06 x |
| P/E ratio 2022 |
21.8
x | P/E ratio 2023 |
27
x | Employees | 181 |
| Yield 2022 |
2.22% | Yield 2023 |
2.02% | Free-Float | 71% |
More Fundamentals
* Assessed data
More news
| 1 week | +1.36% | ||
| Current month | +4.21% | ||
| 1 month | +2.48% | ||
| 3 months | -6.31% | ||
| 6 months | -0.93% | ||
| Current year | -6.42% |
1 week
36.70
37.65
1 month
34.8037.65
Current year
34.7041.35
1 year
28.8044.35
3 years
16.4544.80
5 years
15.0046.60
10 years
13.2046.60
| Managers | Title | Age | Since |
|---|---|---|---|
Ching Huang Lin
CEO | Chief Executive Officer | - | 01/07/01 |
Shu Chin Hsieh
DFI | Director of Finance/CFO | - | 16/07/16 |
Yu Fang Wang
AUD | Comptroller/Controller/Auditor | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fang Chuan Lee
BRD | Director/Board Member | 68 | 12/93/12 |
Te Ming Lu
BRD | Director/Board Member | - | - |
Hung Wen Chiang
BRD | Director/Board Member | - | 28/07/28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 37.15 | 0.00% | 41,520 |
| 20/24/20 | 37.15 | +0.27% | 77,313 |
| 19/24/19 | 37.05 | +0.14% | 62,506 |
| 18/24/18 | 37 | -0.94% | 63,020 |
| 17/24/17 | 37.35 | +1.91% | 262,520 |
End-of-day quote Taipei Exchange, June 21, 2024
More quotes
YUNG ZIP CHEMICAL IND. CO., LTD. is a Taiwan-based company principally engaged in the manufacturing and trading of pharmaceutical ingredient products. Its diclofenac sodium (DCS) is used for the treatment of rheumatoid arthritis, bursitis and inflammation. The acyclovir (ACV) is used for the treatment of herpes virus infections. The miconazole nitrate (MCN) is used for the treatment of yeast infection. The sodium starch glycolate (SSG) is used as disintegrant in pharmaceutical preparation. The Clonidine hydrochloride (CLD) is used for the treatment of hypertension. The Company mainly distributes its products in domestic market and overseas markets, including the United States of America (the USA), Thailand, Indonesia and the Philippines.
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.42% | 48.6M | |
| +51.63% | 796B | |
| +41.51% | 628B | |
| -5.10% | 358B | |
| +19.90% | 331B | |
| +9.95% | 301B | |
| +17.66% | 244B | |
| +3.39% | 228B | |
| +10.75% | 214B | |
| +6.99% | 165B |
- Stock Market
- Equities
- 4102 Stock
